Skip to main content

Table 4 Mutations of EGFR, HER2 and their transducers found in samples from patients.

From: Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas

Sample

EGFR

KRAS

exon 2

PI3K

exon 9

PI3K

exon 20

BRAF

exon 15

PTEN

1

WT

WT

WT

WT

WT

WT

2

WT

WT

WT

WT

WT

WT

3

WT

WT

WT

WT

WT

WT

4

WT

WT

WT

WT

WT

WT

5

WT

WT

WT

WT

WT

WT

6

WT

WT

WT

WT

WT

WT

7

WT

WT

WT

WT

WT

WT

8

WT

WT

WT

WT

WT

WT

9

WT

WT

WT

WT

WT

WT

10

WT

WT

WT

WT

WT

WT

11

WT

WT

WT

WT

WT

WT

12

WT

WT

WT

WT

WT

WT

13

WT

WT

WT

WT

WT

WT

14

WT

WT

WT

WT

WT

WT

15

WT

WT

WT

WT

WT

WT

16

WT

WT

WT

WT

WT

WT

17

WT

WT

WT

WT

WT

WT

18

WT

WT

WT

WT

WT

WT

19

WT

WT

WT

WT

WT

WT

20

WT

WT

WT

WT

WT

WT

21

K757R

WT

WT

WT

WT

WT

22

WT

G13D

WT

WT

V600E

WT

23

WT

G13D

E545K

H1047R

WT

T202I/E235G

24

WT

WT

WT

WT

WT

WT

25

WT

WT

WT

WT

V600E

WT

26

C775Y

WT

WT

WT

WT

WT

27

WT

WT

WT

WT

WT

WT

28

WT

WT

WT

WT

WT

WT

29

V843I

WT

Q546L

WT

WT

F271L

30

WT

WT

WT

WT

WT

WT

31

E872K

WT

E545A

WT

V600E

WT

32

WT

WT

WT

WT

WT

WT

33

WT

WT

WT

WT

WT

WT

34

WT

WT

WT

WT

WT

WT

35

WT

WT

WT

WT

WT

WT

36

T790M

WT

WT

WT

WT

WT

37

WT

WT

WT

WT

WT

WT

38

WT

WT

WT

WT

WT

WT

39

W817STOP

WT

WT

WT

WT

WT

40

WT

WT

WT

WT

WT

WT

41

WT

WT

WT

WT

WT

WT

42

WT

WT

WT

F1059L

WT

WT

43

WT

WT

WT

WT

V600E

WT

44

WT

I24F

WT

WT

WT

WT

45

A864T

WT

WT

WT

WT

WT

46

WT

WT

WT

WT

WT

WT

47

WT

WT

WT

WT

WT

WT

48

WT

WT

WT

WT

WT

WT

49

WT

WT

WT

WT

WT

WT

  1. WT: wild type.